Skip to Content
Merck
CN
  • Reprogramming of tumor-associated macrophages by targeting β-catenin/FOSL2/ARID5A signaling: A potential treatment of lung cancer.

Reprogramming of tumor-associated macrophages by targeting β-catenin/FOSL2/ARID5A signaling: A potential treatment of lung cancer.

Science advances (2020-06-18)
Poonam Sarode, Xiang Zheng, Georgia A Giotopoulou, Andreas Weigert, Carste Kuenne, Stefan Günther, Aleksandra Friedrich, Stefan Gattenlöhner, Thorsten Stiewe, Bernhard Brüne, Friedrich Grimminger, Georgios T Stathopoulos, Soni Savai Pullamsetti, Werner Seeger, Rajkumar Savai
ABSTRACT

Tumor-associated macrophages (TAMs) influence lung tumor development by inducing immunosuppression. Transcriptome analysis of TAMs isolated from human lung tumor tissues revealed an up-regulation of the Wnt/β-catenin pathway. These findings were reproduced in a newly developed in vitro "trained" TAM model. Pharmacological and macrophage-specific genetic ablation of β-catenin reprogrammed M2-like TAMs to M1-like TAMs both in vitro and in various in vivo models, which was linked with the suppression of primary and metastatic lung tumor growth. An in-depth analysis of the underlying signaling events revealed that β-catenin-mediated transcriptional activation of FOS-like antigen 2 (FOSL2) and repression of the AT-rich interaction domain 5A (ARID5A) drive gene regulatory switch from M1-like TAMs to M2-like TAMs. Moreover, we found that high expressions of β-catenin and FOSL2 correlated with poor prognosis in patients with lung cancer. In conclusion, β-catenin drives a transcriptional switch in the lung tumor microenvironment, thereby promoting tumor progression and metastasis.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
XAV939, ≥98% (HPLC)
Sigma-Aldrich
MISSION® esiRNA, targeting human FOSL2